As key enzymes involved in the ubiquitination/deubiquitination process, E3 ubiquitin ligases and DUBs can both play a role in cancer immunotherapy, despite their opposing functions in regulating protein stability and potentially leading to different physiological responses. The gene discussed is PRKN; the disease is cancer.